Pediatric Neurology
Volume 38, Issue 3 , Pages 151-162 , March 2008

Choosing the Correct Antiepileptic Drugs: From Animal Studies to the Clinic

  • Gregory L. Holmes, MD

      Affiliations

    • Corresponding Author InformationCommunications should be addressed to: Dr. Holmes; Section of Neurology, Neuroscience Center at Dartmouth; Dartmouth-Hitchcock Medical Center; One Medical Center Drive; Lebanon, NH 03756.
    • ,
  • Qian Zhao, MD

Received 5 June 2007 ,Accepted 17 September 2007.

References 

  1. Merritt HH, Putnam TJ. A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatry. 1938;39:1003–1015
  2. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:249–260
  3. Matsumoto H, Ajmone-Marsan C. Cortical cellular phenomena in experimental epilepsy: Ictal manifestations. Exp Neurol. 1964;25:305–326
  4. Matsumoto H, Ajmone-Marsan C. Cortical cellular phenomena in experimental epilepsy: Interictal manifestations. Exp Neurol. 1964;80:286–304
  5. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553–564
  6. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: Opposing effects on N-methyl-d-aspartate and GABAA receptors. Ann Neurol. 1994;35:229–234
  7. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl. 1):S3–S9
  8. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: Inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse. 2002;45:171–190
  9. Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of H-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci. 2002;5:767–774
  10. Surges R, Freiman TM, Feuerstein TJ. Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. Epilepsia. 2003;44:150–156
  11. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136:659–672
  12. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861–9866
  13. Ben-Ari Y, Holmes GL. Effects of seizures on developmental processes in the immature brain. Lancet Neurol. 2006;5:1055–1063
  14. Ben-Ari Y, Holmes GL. The multiple facets of gamma-aminobutyric acid dysfunction in epilepsy. Curr Opin Neurol. 2005;18:141–145
  15. Khazipov R, Khalilov I, Tyzio R, Morozova E, Ben-Ari Y, Holmes GL. Developmental changes in GABAergic actions and seizure susceptibility in the rat hippocampus. Eur J Neurosci. 2004;19:590–600
  16. Jensen FE, Baram TZ. Developmental seizures induced by common early-life insults: Short- and long-term effects on seizure susceptibility. Ment Retard Dev Disabil Res Rev. 2000;6:253–257
  17. Khazipov R, Esclapez M, Caillard O, et al. Early development of neuronal activity in the primate hippocampus in utero. J Neurosci. 2001;21:9770–9781
  18. Ben-Ari Y, Cherubini E, Corradetti R, Gaiarsa J-L. Giant synaptic potentials in immature rat CA3 hippocampal neurones. J Physiol (Lond). 1989;416:303–325
  19. Ben-Ari Y. Excitatory actions of GABA during development: The nature of the nurture. Nat Rev Neurosci. 2002;3:728–739
  20. Dzhala VI, Staley KJ. Transition from interictal to ictal activity in limbic networks in vitro. J Neurosci. 2003;23:7873–7880
  21. Nurse S, Lacaille JC. Late maturation of GABA(B) synaptic transmission in area CA1 of the rat hippocampus. Neuropharmacology. 1999;38:1733–1742
  22. Flint AC, Maisch US, Weishaupt JH, Kriegstein AR, Monyer H. NR2A subunit composition shortens NMDA receptor synaptic currents in developing neocortex. J Neurosci. 1997;17:2469–2476
  23. Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341:485–489
  24. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med. 2005;11:1205–1213
  25. Holmes GL. Models for generalized seizures. Clin Neurophysiol. 2004;57(Suppl):415–424
  26. Crunelli V, Leresche N. A role for GABAB receptors in excitation and inhibition of thalamocortical cells. TINS. 1991;14:16–21
  27. Song I, Kim D, Choi S, Sun M, Kim Y, Shin HS. Role of the alpha1G T-type calcium channel in spontaneous absence seizures in mutant mice. J Neurosci. 2004;24:5249–5257
  28. Lin FH, Cao Z, Hosford DA. Increased number of GABAB receptors in the lethargic (lh/lh) mouse model of absence epilepsy. Brain Res. 1993;608:101–106
  29. Snead OC. Basic mechanisms of generalized absence seizures. Ann Neurol. 1995;37:146–157
  30. Hosford DA, Clark S, Cao Z, et al. The role of GABAB receptor activation in absence seizures of lethargic (lh/lh) mice. Science. 1992;257:398–401
  31. Huguenard JR, Prince DA. Clonazepam suppresses GABAB-mediated inhibition in thalamic relay neurons through effects in nucleus reticularis. J Neurophysiol. 1994;71:2576–2581
  32. White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH. Discovery and preclinical development of antiepileptic drugs. In:  Levy RH,  Mattson RH,  Meldrum BS,  Perucca E editor. Antiepileptic drugs. 5th ed.. Philadelphia: Lippincott Williams & Williams; 2002;p. 36–48
  33. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 1997;38(Suppl. 1):S9–S17
  34. White HS, Johnson M, Wolf HH, Kupferberg HJ. The early identification of anticonvulsant activity: Role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital J Neurol Sci. 1995;16:73–77
  35. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia. 1999;40:1471–1483
  36. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: II (Anticonvulsant drug screening). Epilepsia. 1978;19:409–428
  37. Krall RL, Penry JK, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: I (History and a program for progress). Epilepsia. 1978;19:393–408
  38. Kupferberg HJ, Schmutz M. Screening of new compounds and the role of the pharmaceutical industry. In:  Engel J,  Pedley TA editor. Epilepsy: A comprehensive textbook. Philadelphia: Lippincott-Raven; 1997;p. 1417–1434
  39. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998;353:191–206
  40. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (UCB L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther. 1998;284:474–479
  41. Snead OC. Pharmacological models of generalized absence seizures in rodents. J Neural Transm. 1992;35(Suppl):7–19
  42. Stables JP, Bertram E, Dudek FE, et al. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: Summary of the NIH/NINDS/AES Models II Workshop. Epilepsia. 2003;44:1472–1478
  43. McNamara JO. Kindling model of epilepsy. Adv Neurol. 1986;44:303–318
  44. McNamara JO, Byrne MC, Dasheiff RM, Fitz JG. The kindling model of epilepsy: A review. Prog Neurobiol. 1980;15:139–159
  45. McNamara JO. Development of new pharmacological agents for epilepsy: Lessons from the kindling model. Epilepsia. 1989;30(Suppl. 1):S13–S18
  46. Stratton SC, Large CH, Cox B, Davies G, Hagan RM. Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res. 2003;53:95–106
  47. Hashimoto Y, Araki H, Futagami K, Kawasaki H, Gomita Y. Effects of valproate, phenytoin, and zonisamide on clonic and tonic seizures induced by acute and repeated exposure of mice to flurothyl. Physiol Behav. 2003;78:465–469
  48. Loscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs (A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy). Epilepsy Res. 2002;50:105–123
  49. Namba T, Morimoto K, Sato K, Yamada N, Kuroda S. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 1993;638:36–44
  50. Holmes GL, Weber DA. The effect of progesterone on kindling: A developmental study. Brain Res. 1984;318:45–53
  51. Pellis SM, Pellis VC. Posture. In:  Whishaw IQ,  Kolb B editor. The behavior of the laboratory rat (A handbook with tests). Oxford: Oxford University Press; 2005;p. 121–128
  52. Muir G. Locomotion. In:  Whishaw IQ,  Kolb B editor. The behavior of the laboratory rat (A handbook with tests). Oxford: Oxford University Press; 2005;p. 150–161
  53. Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of lamotrigine-associated rash. Epilepsia. 2006;47:318–322
  54. Wolf SM, Shinnar S, Kang H, Gil KB, Moshé SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia. 1995;36:1203–1205
  55. Khurana DS, Riviello J, Helmers S, Holmes G, Anderson J, Mikati MA. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr. 1996;128:829–833
  56. Schubert R. Attention deficit disorder and epilepsy. Pediatr Neurol. 2005;32:1–10
  57. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: A retrospective review. Neurology. 1987;37:379–385
  58. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities: US experience since 1984. Neurology. 1989;39:201–207
  59. Mares P, Haugvicova R. Anticonvulsant action of gabapentin during postnatal development in rats. Epilepsia. 1997;38:893–896
  60. Slamberova R, Mares P, Vorlicek J. Clobazam exerts an anticonvulsant action in immature rats. Physiol Res. 1998;47:301–305
  61. Haugvicova R, Kubova H, Mares P. Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced seizures in developing rats?. Physiol Res. 2002;51:363–370
  62. Stafstrom CE, Holmes GL. Infantile spasms: Criteria for an animal model. Int Rev Neurobiol. 2002;49:391–411
  63. Mackay MT, Weiss SK, Webber T, et al. Practice parameter: Medical treatment of infantile spasms: Report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62:1668–1681
  64. Snead OCI, Benton JW, Myers GL. ACTH and prednisone in childhood seizure disorders. Neurology. 1983;33:966–970
  65. Dobbing J, Sands J. Quantitative growth and development of human brain. Arch Dis Child. 1973;48:757–767
  66. Jensen FE, Blume H, Alvarado S, Firkusny I, Geary C. NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. Epilepsia. 1995;36:966–972
  67. Koh S, Tibayan FD, Simpson JN, Jensen FE. NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia. 2004;45:569–575
  68. Koh S, Jensen FE. Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann Neurol. 2001;50:366–372
  69. Chen K, Baram TZ, Soltesz I. Febrile seizures in the immature rat model modify neuronal excitability long-term. Nat Med. 1999;5:888–894
  70. Dube C, Chen K, Eghbal-Ahmadi M, Brunson K, Soltesz I, Baram TZ. Prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term. Ann Neurol. 2000;47:336–344
  71. Toth Z, Yan X-X, Haftoglou S, Ribak CE, Baram TZ. Seizure-induced neuronal injury: Vulnerability to febrile seizures in an immature rat model. J Neurosci. 1998;18:4285–4294
  72. Dube C, Richichi C, Bender RA, Chung G, Litt B, Baram TZ. Temporal lobe epilepsy after experimental prolonged febrile seizures: Prospective analysis. Brain. 2006;129:911–922
  73. Brewster A, Bender RA, Chen Y, Dube C, Eghbal-Ahmadi M, Baram TZ. Developmental febrile seizures modulate hippocampal gene expression of hyperpolarization-activated channels in an isoform- and cell-specific manner. J Neurosci. 2002;22:4591–4599
  74. Bender RA, Dubé C, Gonzalez-Vega R, Mina EW, Baram TZ. Mossy fiber plasticity and enhanced hippocampal excitability, without hippocampal cell loss or altered neurogenesis, in an animal model of prolonged febrile seizures. Hippocampus. 2004;13:399–412
  75. Dube C, Yu H, Nalcioglu O, Baram TZ. Serial MRI after experimental febrile seizures: Altered T2 signal without neuronal death. Ann Neurol. 2004;56:709–714
  76. Brewster AL, Bernard JA, Gall CM, Baram TZ. Formation of heteromeric hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the hippocampus is regulated by developmental seizures. Neurobiol Dis. 2005;19:200–207
  77. Olson JE, Scher MS, Holtzman D. Effects of anticonvulsants on hyperthermia-induced seizures in the rat pup. Epilepsia. 1984;25:96–99
  78. Dubé CM, Baram TZ. Complex febrile seizures—An experimental model in immature rodents. In:  Pitkänen A,  Schwartzkroin PA,  Moshé S editor. Models of seizures and epilepsy. Burlington, MA: Elsevier; 2006;p. 333–340
  79. Truitt EB, Ebersberger EM, Ling ASC. Measurement of brain excitability by use of hexaflurodiethyl ether (Indoklon). J Pharmacol Exp Ther. 1960;129:445–453
  80. Moshé SL, Velísek L, Holmes GL. Developmental aspects of experimental generalized seizures induced by pentylenetetrazol, bicuculline and flurothyl. In:  Malafosse A,  Genton P,  Hirsch E,  Marescaux C,  Broglin D,  Bernasconi R editor. Idiopathic generalized epilepsies. London: John Libbey; 1994;p. 51–64
  81. Sperber EF, Haas KZ, Romero MT, Stanton PK. Flurothyl status epilepticus in developing rats: Behavioral, electrographic, histological and electrophysiological studies. Dev Brain Res. 1999;116:59–68
  82. Sperber EF, Moshé SL. Age-related differences in seizure susceptibility to flurothyl. Dev Brain Res. 1988;39:295–297
  83. Gatt G, Veliskova J, Liu Z, Moshé SL, Holmes GL. Ontogeny of flurothyl-induced seizures: A behavioral and EEG electroencephalographic analysis. Epilepsia. 1993;34(Suppl. 6):63
  84. Liu Z, Yang Y, Silveira DC, et al. Consequences of recurrent seizures during early brain development. Neuroscience. 1999;92:1443–1454
  85. Riviello P, de Rogalski Landrot I, Holmes GL. Lack of cell loss following recurrent neonatal seizures. Brain Res Dev Brain Res. 2002;135:101–104
  86. Holmes GL, Gairsa JL, Chevassus-Au-Louis N, Ben-Ari Y. Consequences of neonatal seizures in the rat: Morphological and behavioral effects. Ann Neurol. 1998;44:845–857
  87. Huang L, Cilio MR, Silveira DC, et al. Long-term effects of neonatal seizures: A behavioral, electrophysiological, and histological study. Brain Res Dev Brain Res. 1999;118:99–107
  88. McCabe BK, Silveira DC, Cilio MR, et al. Reduced neurogenesis after neonatal seizures. J Neurosci. 2001;21:2094–2103
  89. Wasterlain CG. Effects of neonatal status epilepticus on rat brain development. Neurology. 1976;26:975–986
  90. Wasterlain CG. Neonatal seizures and brain growth. Neuropaediatrie. 1978;9:213–228
  91. Wasterlain CG, Plum F. Vulnerability of developing rat brain to electroconvulsive seizures. Arch Neurol. 1973;29:38–45
  92. Neill J, Liu Z, Sarkisian M, et al. Recurrent seizures in immature rats: Effect on auditory and visual discrimination. Dev Brain Res. 1996;95:283–292
  93. Bo T, Jiang Y, Cao H, Wang J, Wu X. Long-term effects of seizures in neonatal rats on spatial learning ability and N-methyl-d-aspartate receptor expression in the brain. Brain Res Dev Brain Res. 2004;152:137–142
  94. Sogawa Y, Monokoshi M, Silveira DC, et al. Timing of cognitive deficits following neonatal seizures: Relationship to histological changes in the hippocampus. Brain Res Dev Brain Res. 2001;131:73–83
  95. Villeneuve N, Ben-Ari Y, Holmes GL, Gaiarsa JL. Neonatal seizures induced persistent changes in intrinsic properties of CA1 rat hippocampal cells. Ann Neurol. 2000;47:729–738
  96. Isaeva E, Isaev D, Khazipov R, Holmes GL. Selective impairment of GABAergic synaptic transmission in the flurothyl model of neonatal seizures. Eur J Neurosci. 2006;23:1559–1566
  97. Cortez MA, McKerlie C, Snead OC. A model of atypical absence seizures: EEG, pharmacology, and developmental characterization. Neurology. 2001;56:341–349
  98. Persad V, Cortez MA, Snead OC. A chronic model of atypical absence seizures: Studies of developmental and gender sensitivity. Epilepsy Res. 2002;48:111–119
  99. Chan KF, Jia Z, Murphy PA, Burnham WM, Cortez MA, Snead OC. Learning and memory impairment in rats with chronic atypical absence seizures. Exp Neurol. 2004;190:328–336
  100. Stewart LS, Bercovici E, Shukla R, et al. Daily rhythms of seizure activity and behavior in a model of atypical absence epilepsy. Epilepsy Behav. 2006;9:564–572
  101. Chan KF, Burnham WM, Jia Z, Cortez MA, Snead OC. GABAB receptor antagonism abolishes the learning impairments in rats with chronic atypical absence seizures. Eur J Pharmacol. 2006;541:64–72
  102. Stafstrom CE, Moshé SL, Swann JW, Nehlig A, Jacobs MP, Schwartzkroin PA. Models of pediatric epilepsies: Strategies and opportunities. Epilepsia. 2006;47:1407–1414
  103. Kabova R, Liptakova S, Slamberova R, Pometlova M, Velísek L. Age-specific N-methyl-d-aspartate-induced seizures: Perspectives for the West syndrome model. Epilepsia. 1999;40:1357–1369
  104. Mares P, Velísek L. N-methyl-d-aspartate (NMDA)-induced seizures in developing rats. Brain Res Dev Brain Res. 1992;65:185–189
  105. Velísek L, Jehle K, Asche S, Veliskova J. Model of infantile spasms induced by N-methyl-d-aspartic acid in prenatally impaired brain. Ann Neurol. 2007;61:109–119
  106. Stafstrom CE, Sasaki-Adams DM. NMDA-induced seizures in developing rats cause long-term learning impairment and increased seizure susceptibility. Epilepsy Res. 2003;53:129–137
  107. Baram TZ. Pathophysiology of massive infantile spasms: Perspective on the putative role of brain adrenal axis. Ann Neurol. 1993;33:231–236
  108. Welberg LA, Seckl JR, Holmes MC. Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: Possible implications for behaviour. Neuroscience. 2001;104:71–79
  109. Baram TZ. Models for infantile spasms: An arduous journey to the Holy Grail. Ann Neurol. 2007;61:89–91

PII: S0887-8994(07)00459-6

doi: 10.1016/j.pediatrneurol.2007.09.008

Pediatric Neurology
Volume 38, Issue 3 , Pages 151-162 , March 2008

Article Tools

* Image Usage & Resolution